US-based computational drug designer Schrödinger has entered into a multi-year early drug discovery collaboration with Sanofi in which Schrödinger will offer target analysis and validation to lead identification and lead optimization for as many as ten drug discovery programs.
Under the deal, Schrödinger could receive up to $120m, which includes preclinical milestones.
Computer aided design (CAD) plays a major role in nearly all industries ranging from airplane design to movie making but it is not widely recognized as a truly enabling technology in the field of drug discovery.
Additionally, a new enterprise informatics system to facilitate real-time collaboration between computational designers and medicinal chemists, will serve as the communications and project management platform for researchers across the two companies.
Schrödinger president Ramy Farid said: "Our mission is to transform drug discovery through computational technology, and we will continue to commit the resources necessary to develop compelling scientific solutions.
Sanofi president Global R&D Elias Zerhouni said: "Collaborating with Schrödinger is an effective way for Sanofi to gain access to first rate computational design resources.
"In the interest of perpetual innovation, we are constantly looking at cutting-edge technologies to advance our research."
In recent years, Schrödinger has made a number of key scientific breakthroughs in the areas of protein and ligand structure determination and potency prediction which could have a transformative impact on the discovery of drugs.